Key result
High plasma triglyceride levels (3221 +/- 1590 mg/dl) in uncontrolled diabetes were associated with chylomicronemia syndrome symptoms that improved with lipid-lowering therapy.
Why the study?
Does lipid-lowering therapy improve clinical manifestations of chylomicronemia syndrome in patients with uncontrolled non-insulin-dependent diabetes mellitus?
Observational
Does lipid-lowering therapy improve clinical manifestations of chylomicronemia syndrome in patients with uncontrolled non-insulin-dependent diabetes mellitus?
Chylomicronemia syndrome can occur in uncontrolled non-insulin-dependent diabetic patients with familial hypertriglyceridemia, and its clinical manifestations improve with specific lipid-lowering therapy.
Extreme lipemia in uncontrolled diabetes may warrant familial screening; leaves open genetic versus glycemic contributions to severe hypertriglyceridemia.
Lipemic plasma with marked elevations of plasma triglyceride levels (3221 +/- 1590 mg/dl) and fasting chylomicronemia was observed in nine patients with uncontrolled non-insulin-dependent diabetes mellitus. Every case had hypertriglyceridemic relatives, suggesting that the very high triglyceride values seen resulted from the coexistence of diabetes with a familial form of hypertriglyceridemia. A number of clinical and biochemical features observed in the diabetic patients and also in a group of nondiabetic controls with comparable degrees of hypertriglyceridemia suggests that these manifestations are related to high plasma triglyceride levels rather than to the diabetes per se. Chronic abdominal pain, mental confusion, and memory loss improved with lipid-lowering therapy and clearing the plasma of chylomicrons. Pulmonary function tests, red cell 2,3-diphosphoglycerate, and hemoglobin oxygen affinity were normal; the mild hypoxemia observed is believed to be an artifact. It is suggested that a syndrome due to chylomicronemia can occur in uncontrolled non-insulin-dependent diabetic patients, who in addition have a familial form of hypertriglyceridemia. To prevent manifestations of this syndrome in these patients, specific lipid-lowering therapy may be required in addition to control of their diabetes.
No takes yet. Share an insight, caveat, or question.
Chait et al. (1981) conducted an observational in Chylomicronemia syndrome in diabetes mellitus. High plasma triglyceride levels vs. Nondiabetic controls with comparable hypertriglyceridemia was evaluated on Clinical and biochemical features of chylomicronemia syndrome. High plasma triglyceride levels (3221 +/- 1590 mg/dl) in uncontrolled diabetes were associated with chylomicronemia syndrome symptoms that improved with lipid-lowering therapy.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: